Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
supernus.com

See what CB Insights has to offer

Founded Year

1990

Stage

IPO | IPO

Total Raised

$60M

Date of IPO

5/1/2012

Market Cap

1.63B

Stock Price

30.61

Revenue

$0000 

About Supernus Pharmaceuticals

Supernus Pharmaceuticals (NASDAQ: SUPN) develops products for the treatment of central nervous system, or CNS, diseases. The company is developing several product candidates in neurology and psychiatry to address market opportunities in epilepsy and attention deficit hyperactivity disorder, or ADHD, including ADHD patients with impulsive aggression.

Supernus Pharmaceuticals Headquarter Location

9715 Key West Avenue

Rockville, Maryland, 20850,

United States

301-838-2500

Latest Supernus Pharmaceuticals News

USD 444.54 mn growth for Dravet Syndrome Treatment Market by 2025 |Evolving Opportunities with Cadila Healthcare Ltd. & Epygenix Therapeutics Inc.|17000+ Technavio Reports

Nov 26, 2021

|Evolving Opportunities with Cadila Healthcare Ltd. & Epygenix Therapeutics Inc.|17000+ Technavio Reports News provided by Share this article Share this article NEW YORK, Nov. 25, 2021 /PRNewswire/ -- The " Dravet Syndrome Treatment Market - Competitive Analysis, Trends, Drivers, Challenges, and Five Force Analysis " report has been added to Technavio's offering. The dravet syndrome treatment market size is expected to increase by USD 444.54 million, at a CAGR of  9.41% from 2020 to 2025. 39% of the market's growth will originate from North America. The US and Canada are the key markets for the Dravet syndrome treatment market in North America. Attractive Opportunities in Dravet Syndrome Treatment Market by Product and Geography - Forecast and Analysis 2021-2025 Market Dynamics The market is driven by factors such as the rising strategic alliances, increasing new product launches, and the growth in special regulatory designations. However, low awareness is hindering market growth. Company Profiles The dravet syndrome treatment market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market. Some of the companies covered in this report are AbbVie Inc., BIOCODEX SAS, Cadila Healthcare Ltd., Epygenix Therapeutics Inc., H. Lundbeck AS, PTC Therapeutics Inc., Supernus Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Zogenix Inc., etc. Key Offerings of Few Companies - AbbVie Inc. - The company offers Stiripentol under the brand name of Diacomit which is used for the treatment of Dravet syndrome. BIOCODEX SAS -  The company provides Brivaracetam tablets which help to cure Dravet syndrome. Cadila Healthcare Ltd - The company provides medicines such as EPX 100, 101, 102, 103, and others for the treatment of Dravet syndrome. Competitive Analysis The competitive scenario provided in the Dravet syndrome treatment market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc. Market Segmentation By Product, the market is classified into SGDs, TGDs, and FGDs.The dravet syndrome treatment market share growth by the SGDs segment has been significant By Geography, the market is classified as North America, Europe, Asia, and ROW. North America will have the largest share of the market. Related Reports - Sjogren's Syndrome Therapeutics Market -The Sjogren's syndrome therapeutics market size has the potential to grow by USD 287.68 million during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 4.05%. Download a free sample now! Dry Eye Syndrome Drugs Market -The dry eye syndrome drugs market size has the potential to grow by USD 2.08 billion during 2021-2025, and the market's growth momentum will accelerate at a CAGR of 6.81%. Download a free sample now! Dravet Syndrome Treatment Market Scope Report Coverage Companies profiled AbbVie Inc., BIOCODEX SAS, Cadila Healthcare Ltd., Epygenix Therapeutics Inc., H. Lundbeck AS, PTC Therapeutics Inc., Supernus Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Zogenix Inc. Market Dynamics Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period Customization preview If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Supernus Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Supernus Pharmaceuticals is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Supernus Pharmaceuticals Patents

Supernus Pharmaceuticals has filed 88 patents.

The 3 most popular patent topics include:

  • Amines
  • Piperidines
  • Abandoned drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/23/2021

11/9/2021

Calcium channel blockers, Pharmacokinetics, Anticonvulsants, Amines, Hepatotoxins

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/23/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/9/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Calcium channel blockers, Pharmacokinetics, Anticonvulsants, Amines, Hepatotoxins

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Supernus Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Supernus Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.